Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis

Budakoglu B., Abali H., Uncu D., Yildirim N., Öksüzoglu B., ZENGİN N.

Journal of Chemotherapy, cilt.17, sa.4, ss.452-453, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 4
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1179/joc.2005.17.4.452
  • Dergi Adı: Journal of Chemotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.452-453
  • Anahtar Kelimeler: colorectal cancer, hemodialysis, irinotecan, RANDOMIZED-TRIAL, FLUOROURACIL, FAILURE
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Pharmacokinetic properties of many antineoplastic agents or their metabolites change with organ dysfunction. Unfortunately, chemotherapy doses determined in phase I and II studies in patients with normal hepatic and renal reserves are not usually applicable to those with hepatic and/or renal dysfunction. Considering the high incidence of colorectal adenocarcinoma, it is not unusual for a colorectal cancer patient to be on chronic hemodialysis. We report a patient with metastatic colorectal cancer on chronic hemodialysis who tolerated weekly irinotecan at 50 mg/m2 well without significant toxicity. We briefly discuss therapeutic dose modification in such patients. © E.S.I.F.T. srl - Firenze.